Vertex Pharmaceuticals agreed to a collaboration deal with the pre-clinical biotech Entrada Therapeutics, Thursday. The two companies announced a global partnership to develop intracellular Endosomal Escape Vehicle (EEV) therapeutics.
If you are not happy with the results below please do another search
50 search results for:
Novartis reported Thursday that a Phase III trial of iptacopan met its primary endpoint in paroxysmal nocturnal hemoglobinuria (PNH) – the company’s second win in this indication in as many months.
The EU Health Commissioner will on Friday propose extending the deadline for companies to comply with a new law regulating medical devices, she told Reuters on Thursday as doctors warn the legislation is causing shortages of lifesaving equipment.
The U.S. Food and Drug Administration on Thursday authorized updated COVID-19 booster shots from Moderna and Pfizer and its partner BioNTech for children as young as 6 months of age.
Malaria-related deaths fell slightly in 2021 after a significant increase in the first year of COVID-19, but remained higher than the pre-pandemic estimated toll, according to a World Health Organization (WHO) report on Thursday.
Japanese company Takeda’s dengue vaccine was authorized for use in the European Union on Thursday, making it the second approved vaccine for the mosquito-borne disease that causes millions of infections annually.
Germany’s Bayer has been ordered to pay compensation of 11,135 euros ($11,700) to a French farmer who inhaled fumes from a weedkiller, ending a 15-year legal battle.
Sun Pharmaceutical Industries Ltd.’s drug shipments from its Gujarat plant could be refused entry in its key U.S. market after the drug regulator slapped an import alert on the facility, the drugmaker said on Thursday.
France’s Haute Autorite de Sante public health body advised the government not to use Valneva’s VLA2001 COVID-19 vaccine as part of its wider vaccination strategy, although two rival products should be included as booster shots.
Global talks have begun on drafting new health rules for combating pandemics, and developing nations are lobbying for fairer access to treatments than they got during COVID-19. But they worry that the odds of a favourable outcome from a scheduled 18 months of negotiations at the World Health Organization (WHO) are already stacked against them, as they lack the negotiating firepower of wealthier countries.